New data strengthen profile for Pharmacyclics' novel blood cancer drug
This article was originally published in Scrip
Executive Summary
The clinical profile of Pharmacyclics' novel anticancer PCI-32765 – licensed last week to Janssen for an upfront payment of $150 million – has been boosted from data presented at the American Society of Hematology meeting in San Diego.